NASDAQ$EWTX
Edgewise Therapeutics Inc · Q4 2024 earnings
Q4 2024 earnings · · Before market open · Investor relations
Briefing
Edgewise Therapeutics reported fourth quarter and full year 2024 financial results and provided recent business highlights.
Edgewise Therapeutics reported positive Phase 2 CANYON results, completed enrollment in GRAND CANYON, and advanced CIRRUS-HCM in Q4 2024. The company's cash, cash equivalents, and marketable securities were approximately $470.2 million as of December 31, 2024.
- Completed enrollment of the GRAND CANYON global pivotal study of sevasemten in Becker muscular dystrophy.
- Announced positive top-line results from Phase 2 CANYON trial of sevasemten in Becker.
- On track to report data from Phase 2 CIRRUS-HCM trial of EDG-7500 in Hypertrophic Cardiomyopathy in the first quarter of 2025.
- On track to report data from the Phase 2 LYNX and FOX trials of sevasemten in Duchenne muscular dystrophy in the first half of 2025.
Headline financials
Revenue & EPS history
Edgewise Therapeutics · Revenue · Quarterly
$0
Forward guidance
Edgewise Therapeutics anticipates several milestones in 2025, including data readouts from ongoing clinical trials and regulatory interactions.
Tailwinds
- Reporting data from Phase 2 CIRRUS-HCM trial of EDG-7500 in HCM in Q1 2025.
- Reporting data from Phase 2 LYNX and FOX trials of sevasemten in Duchenne in the first half of 2025.
- Engaging the U.S. FDA in the first half of 2025 to discuss marketing authorization filing strategies for sevasemten in Becker.
- Filing an investigational new drug application for a novel candidate for the treatment of heart failure during 2025.
- Selecting a proprietary cardiometabolic drug candidate based on preclinical proof-of-concept data during 2025.
Headwinds
- Potential risks associated with product candidates causing serious adverse events.
- Uncertainties related to regulatory approval processes.
- Risks related to reliance on third-party manufacturers.
- Risks related to not achieving adequate market acceptance.
- Dependence on the success of sevasemten and EDG-7500.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2024
-0.2%
Avg return
Earnings day
+0.7%
Avg return
5 days after
-4.0%
Avg return
30 days after
40%
8 / 20 earnings
Positive
+16.0%
Q2 2022
Best reaction
-12.3%
Q1 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | -1.7% | -4.3% | +2.4% | |
| Q3 2025 | -1.7% | +23.7% | +35.8% | |
| Q2 2025 | -4.1% | -0.9% | +15.2% | |
| Q1 2025 | +2.4% | +1.0% | +5.8% | |
| Q4 2024 | -2.4% | +7.0% | -40.7% | |
| Q3 2024 | -0.7% | -3.9% | -11.0% | |
| Q1 2024 | -12.3% | -16.5% | -15.5% | |
| Q4 2023 | -1.3% | -3.7% | -7.1% | |
| Q3 2023 | -10.7% | +5.5% | +13.0% | |
| Q2 2023 | +3.4% | +12.5% | -3.4% | |
| Q1 2023 | -6.5% | -5.5% | -2.8% | |
| Q4 2022 | -3.0% | -2.8% | -30.3% | |
| Q3 2022 | +1.8% | +2.1% | -5.7% | |
| Q2 2022 | +16.0% | +6.8% | +17.1% | |
| Q1 2022 | +1.6% | -0.8% | -18.9% | |
| Q4 2021 | +13.0% | -2.5% | -19.3% | |
| Q3 2021 | -1.8% | -3.4% | -3.1% | |
| Q2 2021 | -5.6% | -10.6% | -7.9% | |
| Q1 2021 | +5.2% | +4.7% | -1.6% | |
| Q4 2020 | +5.2% | +4.7% | -1.6% | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro